| Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates JN Torres, LV Paul, TC Rodwell, TC Victor, AM Amallraja, A Elghraoui, ... Emerging microbes & infections 4 (1), 1-9, 2015 | 129 | 2015 |
| Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine C Röcken, A Amallraja, C Halske, L Opasic, A Traulsen, HM Behrens, ... Genome Medicine 13, 1-19, 2021 | 30 | 2021 |
| Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies A Hendricks, A Amallraja, T Meißner, P Forster, P Rosenstiel, ... Cancers 12 (2), 393, 2020 | 4 | 2020 |
| Case report: 16-yr life history and genomic evolution of an ER+ HER2− breast cancer B Xu, A Amallraja, P Swaminathan, R Elsey, C Davis, S Theel, S Viet, ... Molecular Case Studies 6 (6), a005629, 2020 | 2 | 2020 |
| Diagnostic Utility of Comprehensive RNA-Seq Analysis in Adult B-ALL N Farnoud, K Liosis, D Leongamornlert, J Gutiérrez-Abril, JE Arango Ossa, ... Blood 142 (Supplement 1), 1601-1601, 2023 | 1 | 2023 |
| RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue M Forster, A Mark, F Egberts, E Rosati, E Rodriguez, M Stanulla, ... Oncotarget 9 (64), 32362, 2018 | 1 | 2018 |
| Abstract PD8-10: APOBEC mutation signature in breast cancer correlates with tumor mutation burden and poor responses to therapy T Meissner, A Amallraja, S Willis, R Harris, B Leyland-Jones, C Williams Cancer Research 78 (4_Supplement), PD8-10-PD8-10, 2018 | 1 | 2018 |
| PANCeq-development and validation of a targeted sequencing assay for detection of mutations and copy number changes in most recurrently mutated driver genes T Meissner, A Amallraja, BM Young, A Mark, C Conolly, A Andrews, ... Cancer Research 77 (13_Supplement), 5355-5355, 2017 | 1 | 2017 |
| Abstract P1-05-22: The value of RNA-Seq for the detection of clinically actionable targets in breast cancer-A small cohort analysis T Meissner, A Amallraja, A Mark, A Andrews, C Connolly, B Young, P De, ... Cancer Research 77 (4_Supplement), P1-05-22-P1-05-22, 2017 | 1 | 2017 |
| Abstract P1-05-23: Utilities and challenges of RNA-Seq based expression and variant calling in a clinical setting B Young, A Mark, T Meissner, A Amallraja, A Andrews, C Connolly, ... Cancer Research 77 (4_Supplement), P1-05-23-P1-05-23, 2017 | 1 | 2017 |
| Genomic Characterization and Classification of BCL6 Rearranged Follicular Lymphomas A Amallraja, G Gundem, D Domenico, JEA Ossa, U Aypar, J Baik, M Kluk, ... Blood 144, 1589, 2024 | | 2024 |
| AD e Novo Supernumerary Ring Chromosome 1 Causes B-Cell Acute Lymphoblastic Leukemia in Monozygotic Twins Due to Independent and Partially Convergent Evolutionary Trajectories J Gutiérrez-Abril, G Gundem, E Fiala, K Liosis, N Farnoud, ... Blood 142, 4352, 2023 | | 2023 |
| Session 3: CancerTrialMatch: a web application for the curation and matching of clinical trials at a precision oncology center P Swaminathan, S Kapadia, A Amallraja, C Williams, T Meissner | | 2023 |
| 54. CancerTrialMatch: A computational resource for the management of clinical trials at a precision oncology center A Amallraja, S Kapadia, P Swaminathan, C Williams, T Meissner Cancer Genetics 268, 18, 2022 | | 2022 |
| TrialMatch: A computational resource for the management of biomarker-based clinical trials at a precision oncology center A Amallraja, S Kapadia, P Swaminathan, C Williams, T Meissner Cancer Research 82 (12_Supplement), 1899-1899, 2022 | | 2022 |
| Landscape of tumor genetic testing and targeted therapies over an eight-year span in a rural population. CB Williams, S Guin, R Elsey, T Meißner, B Xu, Y Sun, A Amallraja, T Jun, ... Journal of Clinical Oncology 40 (16_suppl), e15036-e15036, 2022 | | 2022 |
| Session 3: Understanding the Multi-scale Heterogeneity in Cancer Genomes A Amallraja | | 2022 |
| Very low coverage whole genome sequencing improves clinically relevant copy number variation calling compared to targeted sequencing A Amallraja, J Fuß, CB Williams, M Forster, S Hinz, T Meißner, ... Cancer Research 80 (16_Supplement), 3617-3617, 2020 | | 2020 |
| Clinical benefit of molecularly-guided treatment strategies on progression free survival in patients with advanced gastrointestinal malignancies B Buzard, T Gonser, M Hinrichsen, A Amallraja, K Williams, P De, ... Cancer Research 79 (13_Supplement), 5147-5147, 2019 | | 2019 |
| Characterization of Fluoroquinolone Resistance in Mycobacterium tuberculosis Clinical Isolates Using Molecular Dynamicsand Targeted Genome Wide Variant … A Amallraja San Diego State University, 2018 | | 2018 |